[Elsevier] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study |
|
This post will be closed automatically in 2026-11-16 09:51
Reward10points
|
| |
10
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
10
Structural characterization and structure-activity relationship of polysaccharides from Curcuma kwangsiensis extracted sequentially: Anti-Alzheimer\'s activity in an AlCl3-induced zebrafish model
10
Utilidad pron車stica de la ecograf赤a a pie de cama previa al alta en pacientes con insuficiencia card赤aca aguda y fracci車n de eyecci車n preservada
10
SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
